

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

India approves Corbevax as first heterologous COVID-19 booster shot for 18+

11 August 2022 | News

CORBEVAX is expected to be available as a Booster dose on the CoWIN App in Public and Private Vaccination Centres from August 12, 2022



Hyderabad-based Biological E has announced that its COVID-19 vaccine CORBEVAX has been approved by the Union Health Ministry as a heterologous COVID-19 booster dose under emergency use authorization for individuals aged 18 years and above after six months of administration of primary vaccination (two doses) of COVAXIN or COVISHIELD vaccine.

The Union Health Ministry's approval is based on the recommendations made recently by the COVID-19 Working Group of the National Technical Advisory Group on Immunisation (NTAGI). This approval came after the Drug Controller General of India (DCGI) approved the vaccine for emergency use as a heterologous COVID-19 booster dose for individuals aged 18 years on June 4, 2022. CORBEVAX had received emergency use authorization as a primary two-dose vaccination regimen in adults, adolescents and children five years and above, in a series of approvals from December'21 to April'22.

The price of CORBEVAX for private COVID-19 vaccination centres is Rs 250, inclusive of GST. For the end-user, the price is Rs 400, including taxes and administrative charges.